Mira Pharmaceuticals, INC 10-Q quarterly reports

MIRA Pharmaceuticals, Inc. filed its Q2 2026 Form 10-Q, detailing ongoing net losses, significant cash burn, and substantial doubt regarding its ability to continue as a going concern, alongside Nasdaq minimum bid price non-compliance.

MIRA Pharmaceuticals reports a decrease in net loss for Q1 2026 compared to the prior year, driven by lower operating expenses, while advancing its drug candidates.

MIRA Pharmaceuticals reports a significant increase in assets and equity driven by the SKNY acquisition, while continuing clinical trials for its drug candidates.

MIRA Pharmaceuticals reports significant cash burn and Nasdaq non-compliance, raising substantial doubt about its ability to continue as a going concern, despite advancing its neuroscience drug pipeline.

MIRA Pharmaceuticals announces Q1 2025 results, highlighting progress in Ketamir-2 clinical trials and a planned acquisition of SKNY Pharmaceuticals to expand its drug development pipeline.

MIRA Pharmaceuticals reported a net loss of $5.45 million for the nine months ended September 30, 2024, while advancing the development of its lead drug candidate, MIRA-55.

MIRA Pharmaceuticals has filed an amended quarterly report, disclosing the discovery of a new lead drug candidate, MIRA-55, and ongoing financial challenges.

MIRA Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting ongoing research and development efforts for its drug candidates, Ketamir-2 and MIRA-55.

MIRA Pharmaceuticals reported its first quarter 2024 results, highlighting a shift in focus to MIRA-55 after discovering it was the molecule used in prior pre-clinical trials.